Berotralstat is a selective, orally active plasma kallikrein inhibitor used in research and clinical development, including prophylaxis studies for hereditary angioedema and investigational work on edema and glioblastoma models. This item is provided as a research-grade solid standard (5 mg) intended for analytical, preclinical, and formulation studies, with documented batch-level characterization and supporting analytical data.
- Selective plasma kallikrein inhibitor for HAE and related research
- Supplied as a 5 mg research-grade solid suitable for analytical use
- High HPLC purity (reported ~99.7%) for reliable results
- Documented certificate of analysis and batch data available
- Suitable for biochemical assays, formulation studies, and reference standards